Essilor: Capital Increase Reserved for Employees
2015年12月8日 - 2:00AM
ビジネスワイヤ(英語)
Regulatory News:
At the Extraordinary Shareholders’ Meeting of May 5, 2015,
Essilor International’s (Paris:EI) Board of Directors was given a
21-month authorization to issue shares to members of Essilor
employee stock ownership plans (13th resolution). The maximum
number of common shares authorized for issuance was set at
3,241,992, representing no more than 1.5% of capital stock.
At its meeting on December 2, 2015, the Board of Directors
decided to use this authorization to issue up to 350,000 common
shares for subscription by members of the Essilor / BBGR / Novacel
Ophtalmique / Novisia / BNL Eurolens / Delamare Sovra / OMI / DAC
Vision / Transitions Optical Distribution Ltd employee stock
ownership plans. The new shares will carry rights as from January
1st, 2015. They will be offered at a price of €97.05 per share,
corresponding to the average of the opening prices quoted over the
last twenty trading days preceding the Board’s December 2, 2015
decision to issue the shares, less a 20% discount.
The purpose of this offer is to associate the Company’s
employees with its development by allowing them to become
shareholders of Essilor. The shares may be purchased through two
funds. These funds have been given a specific value since January
1st, 2015, the start date of the subscription period. The closing
date of the subscription period is December 10, 2015. The actual
number of shares issued will be announced on December 21, 2015 and
the Company will then apply for the new shares (par value: €0.18)
to be listed on Euronext Paris.
The Company's capital stock amounts to €38,903,907.06,
represented by 216,132,817 shares.
About EssilorThe world's leading ophthalmic optics
company, Essilor designs, manufactures and markets a wide range of
lenses to improve and protect eyesight. Its mission is to improve
lives by improving sight. To support this mission, Essilor
allocates more than €180 million to research and innovation every
year, in a commitment to continuously bring new, more effective
products to market. Its flagship brands are Varilux®, Crizal®,
Transitions®, Definity®, Xperio®, Optifog®, Foster Grant®, BolonTM
and Costa®. It also develops and markets equipment,
instruments and services for eyecare professionals.Essilor reported
consolidated revenue of nearly €5.7 billion in 2014 and employs
58,000 people. It markets its products in more than 100 countries
and has 33 plants, 490 prescription laboratories and edging
facilities, as well as several research and development centers
around the world. For more information, please visit
www.essilor.com.The Essilor share trades on the Euronext Paris
market and is included in the Euro Stoxx 50 and CAC 40
indices.Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA;
Bloomberg: EI:FP.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151207005950/en/
EssilorInvestor Relations and Financial
CommunicationsPhone: +33 (0)1 49 77 42 16
Eurogas (CSE:EI)
過去 株価チャート
から 11 2024 まで 12 2024
Eurogas (CSE:EI)
過去 株価チャート
から 12 2023 まで 12 2024